GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Geratherm Medical AG (XTER:GME) » Definitions » Capex-to-Revenue

Geratherm Medical AG (XTER:GME) Capex-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Geratherm Medical AG Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Geratherm Medical AG's Capital Expenditure for the three months ended in Jun. 2023 was €0.00 Mil. Its Revenue for the three months ended in Jun. 2023 was €0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Geratherm Medical AG Capex-to-Revenue Historical Data

The historical data trend for Geratherm Medical AG's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geratherm Medical AG Capex-to-Revenue Chart

Geratherm Medical AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.15 0.10 0.05 0.10

Geratherm Medical AG Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.18 0.09 0.04 -

Competitive Comparison of Geratherm Medical AG's Capex-to-Revenue

For the Medical Devices subindustry, Geratherm Medical AG's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geratherm Medical AG's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Geratherm Medical AG's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Geratherm Medical AG's Capex-to-Revenue falls into.



Geratherm Medical AG Capex-to-Revenue Calculation

Geratherm Medical AG's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.739) / 27.44
=0.10

Geratherm Medical AG's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geratherm Medical AG  (XTER:GME) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Geratherm Medical AG Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Geratherm Medical AG's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Geratherm Medical AG (XTER:GME) Business Description

Traded in Other Exchanges
Address
Fahrenheitstrasse 1, Geratal, DEU, 99331
Geratherm Medical AG is a Germany-based medical technology company. The firm operates through four segments: Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Healthcare Diagnostic segment which generates majority revenue provides analog and digital products for measuring body temperature, blood pressure monitors and other products for measuring temperature, as well as related accessories. Medical Warming Systems offers solutions for temperature management at all stages in the pre-clinical and clinical care of the patients, such as rescue situations and operations. Cardio/Stroke segment comprises products for preventing strokes. The Respiratory segment focuses on the development and production of products for pulmonary functional diagnostics.
Executives
Dr. Gert Frank Supervisory Board
Christian Frick Board of Directors

Geratherm Medical AG (XTER:GME) Headlines

From GuruFocus

GameStop Announces CFO Change

By Business Wire Business Wire 07-08-2022

GameStop Launches Wallet for Cryptocurrencies and NFTs

By Business Wire Business Wire 05-23-2022

2 Stocks Primed for a Short Squeeze

By Ben Alaimo 05-17-2022

GameStop Announces Release Date for Third Quarter Fiscal 2022 Results

By Business Wire Business Wire 11-28-2022

GameStop Corp (GME) Reports Narrowed Net Loss in Q3 2023

By GuruFocus Research 12-06-2023

GameStop Announces Release Date for First Quarter Fiscal 2022 Results

By Business Wire Business Wire 05-23-2022

GameStop Announces Release Date for First Quarter Fiscal 2023 Results

By Business Wire Business Wire 05-30-2023

GameStop Discloses Second Quarter 2023 Results

By Marketwired 09-06-2023